Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Keryx Biopharmaceuticals
This is a Phase 4, 48-week, randomized, open-label, multicenter clinical study comprised of 2 periods: a 24-week Dose Titration Period, followed by a 24-week Dose Maintenance Period. The study will consist of 12 scheduled clinic visits over a period of 48 weeks and additional visits as needed.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Estimated glomerular filtration rate ≥20 mL/min and \<60 mL/min
Hgb ≥8.5 g/dL and ≤11.5 g/dL
Serum ferritin ≤500 ng/mL and transferrin saturation (TSAT) ≤25%
Serum intact parathyroid hormone ≤600 pg/mL
You may not be if
Serum phosphate \<3.0 mg/dL
Intravenous (IV) iron administered within 4 weeks prior to Screening
Erythropoiesis-stimulating agents (ESA) administered within 4 weeks prior to Screening
Blood transfusion within 4 weeks prior to Screening
Clareo Health | KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
